Icm Val Daurelle

Montpellier 34298

1 studies enrolling now · 12 studies all time

What they study most

Advanced Colorectal Cancer, Advanced Malignancies, BRAF V600E-mutant Metastatic Colorectal Cancer, Breast Cancer, Cancer of the Prostate, Carcinoma of the Cervix, Stage IVB, Colorectal Cancer, Colorectal Cancer Metastatic, Esophageal Squamous Cell Carcinoma (ESCC), Hormone Sensitive Prostate Cancer, Low Grade Ovarian Serous Adenocarcinoma, Nonmetastatic Castration-Resistant Prostate Cancer

Studies at this site

• A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors — Recruiting now
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — Completed
• Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix — Completed
• Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer — Completed
• Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer — Completed
• EO4010 in Previously Treated Metastatic Colorectal Carcinoma — Stopped early
• SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study — Stopped early
• A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation — Running, not enrolling
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed